Alterations of p53 and expression of WAF1/p21 in human thyroid tumors

Thyroid

Volumn 6, Issue 1, 1996, Pages 1-9

  Zedenius, Jan ^a   Larsson, Catharina ^a   Wallin, Göran ^a   Bäckdahl, Martin ^a   Aspenblad, Ulla ^a   Höög, Anders ^a   Børresen, Anne Lise ^b   Auer, Gert ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P21; PROTEIN P53;

ANAPLASTIC CARCINOMA; ARTICLE; FOLLICULAR CARCINOMA; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PAPILLARY CARCINOMA; PRIORITY JOURNAL; SEQUENCE ANALYSIS; THYROID CARCINOMA; THYROID PARAFOLLICULAR CELL; THYROID TUMOR;

EID: 0029867216     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.1996.6.1     Document Type: Article

References (41)

1. Harris CC, Hollstein M 1993 Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318-1327.
2. Greenblatt MS, Bennett WP, Hollstein M, Harris CC 1994 Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878.
3. Vogelstein B, Kinzler KW 1992 p53 function and dysfunction. Cell 70:523-526.
4. Lane DP 1993 A death in the life of p53. Nature (London) 362:786-787.
5. El-Deiry WS, Tokino T, Velculesco VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B 1993 WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
6. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ 1993 The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.
7. Chen X, Bargonetti J, Prives C 1995 p53, through p21 (WAF1/CIP1), induces cyclin D1 synthesis. Cancer Res 55:4257-4263.
8. El-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculesco VE, Burrell M, Hill DE, Healy E, Rees JL, Hamilton SR, Kinzler KW, Vogelstein B 1995 Topological control of p21 WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 55:2910-2919.
9. Namba H, Hara T, Tukazaki T, Migita K, Ishikawa N, Ito K, Nagataki S, Yamashita S 1995 Radiation-induced G(1) arrest is selectively mediated by the p53-WAF1/Cip1 pathway in human thyroid cells. Cancer Res 55:2075-2080.
10. El-Deiry WS, Harper JW, O'Connor PM, Velculesco VE, Canman CE, Jackman J, Pietenpol JA, Burrel M, Hill DE, Wang YS, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B 1994 WAF1/CIP1 is induced in p53-mediated G(1) arrest and apoptosis. Cancer Res 54:1169-1174.
11. Chang FJ, Syrjanen S, Syrjanen K 1995 Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 13:1009-1022.
12. Zambetti GP, Levine AJ 1993 A comparison of the biological activities of wild-type and mutant p53. FASEB J 7:855-865.
13. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, Hayashi Y, Dohi K, Nakamura N, Akiyama M 1992 Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 52:1369-1371.
14. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang S-H, Koeffler HP 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184.
15. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti, MA 1993 Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91:1753-1760.
16. Zou M, Shi Y, Farid NR 1993 p53 mutations in all stages of thyroid carcinomas. J Clin Endocrinol Metab 77: 1054-1058.
17. Dobashi Y, Sugimura H, Sakamoto A, Mernyei M, Mori M, Oyama T, Machinami R 1994 Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. Diagn Mol Pathol 3:9-14.
18. Holm R, Nesland JM 1994 Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid gland. J Pathol 172:267-272.
19. Dobashi Y, Sakamoto A, Sugimura H, Mernyei M, Mori M, Oyama T, Machinami R 1993 Over-expression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol 17:375-381.
20. Simon D, Goretzki P, Gorelev V, Ebling B, Reishaus E, Lyons J, Haubruck H, Röher HD 1994 Significance of P53 in human thyroid tumors. World J Surg 18:535-541.
21. Hall PA, Ray A, Lemoine NR, Midgley CA, Krausz T, Lane DP 1991 p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet 338:513.
22. Tennvall J, Lundell G, Hallquist A, Wahlberg P, Wallin G, Tibblin S 1994 Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Cancer 74:1348-1354.
23. Hedinger CE, Williams ED, Sobin LH 1988 Histological Typing of Thyroid Tumours. The WHO International Histological Classification of Tumours, 2nd rev ed. Springer-Verlag, Berlin.
24. Shi SR, Key ME, Kalra KL 1991 Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39:741-748.
25. Andersen TI, Børresen A-L 1995 Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Diagn Mol Pathol 4:203-211.
26. Jones MH, Nakamura Y 1992 Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism. Genes Chromosom Cancer 5:89-90.
27. Ishimaru G, Ookawa K, Yamaguchi N, Sakamoto M, Hirohashi S, Muto T, Yokota J 1994 Allelic losses associated with the metastatic potential of colorectal carcinoma. Int J Oncol 5:267-273.
28. Zedenius J, Wallin G, Svensson A, Grimelius L, Höög A, Lundell G, Bäckdahl M, Larsson C 1995 Allelotyping of follicular thyroid tumors. Hum Genet 96:27-32.
29. Hall PA, McKee PH, Menage HD, Dover R, Lane DP 1993 High levels of p53 protein in UV-irradiated normal human skin. Oncogene 8:203-207.
30. Ory K, Legros Y, Auguin C, Soussi T 1994 Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 13:3496-3504.
31. Hann BC, Lane DP 1995 The dominating effect of mutant p53. Nature Genet 9:221-222.
32. Wynford-Thomas D 1992 p53 in tumour pathology: can we trust immunocytochemistry? J Pathol 166:329-330.
33. Zusman I 1995 The clinical relevance of p53 oncoprotein determination in cancer diagnosis and prognosis. Oncol Rep 2:143-150.
34. McKee PH, Hobbs C, Hall PA 1993 Antigen retrieval by microwave irradiation lowers immunohistological detection thresholds. Histopathology 23:377-379.
35. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B 1992 Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature (London) 355:846-847.
36. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ, Reed SI 1994 p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013-1023.
37. Wyllie FS, Haughton MF, Blaydes JP, Schlumberger M, Wynford-Thomas D 1995 Evasion of p53-mediated growth control occurs by three alternative mechanisms in transformed thyroid epithelial cells. Oncogene 10:49-59.
38. Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngo L, Feitelson MA, Jay G 1995 Functional inactivation but not structural mutation of p53 causes liver cancer. Nature Genet 9:41-47.
39. Moll UM, LaQuaglia M, Bénard J, Riou G 1995 Wild-type p53 protein undergoes cytoplasmatic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 92:4407-4411.
40. Czyz W, Joensuu H, Pylkkänen L, Klemi PJ 1994 p53 pro tein, PCNA staining, and DNA content in follicular neoplasms of the thyroid gland. J Pathol 174:267-274.
41. Flaman J-M, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino A-P, Limacher J-M, Bron L, Benhattar J, Tada M, Van Meir EG, Estreicher A, Iggo RD 1995 A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 92:3963-3967.